Erbitux prolongs survival in head/neck cancer study

(Reuters) - Data presented on Saturday at the American Society of Clinical Oncology annual meeting in Chicago found Erbitux patients lived an average of 10.1 months, while those who received only the chemotherapy regimen had a median overall survival of 7.4 months, researchers said.




The survival difference of 2.7 months was considered to be statistically significant.


Read more at Reuters.com Government Filings News

U.S. Dollar Rises to Four-Month High Versus Yen on Jobs, Factory Growth

(Bloomberg) -- The dollar rose to a four-month
high against the yen as accelerating U.S. job growth and
stronger manufacturing added to signs the economy is
gaining momentum.

The U.S. currency closed this week near a seven-week
high versus the euro as reports encouraged traders to
reduce bets on a cut in borrowing costs by the Federal
Reserve. The central bank said in minutes of its May 9
meeting released this week that it still expects a pickup
in the economy this year and views inflation as its main
concern.


Read more at Bloomberg Currencies News

With few options, Bancrofts soften Dow Jones stance

(Reuters) - The Bancroft family that controls Dow Jones & Co. has been criticized a lot in recent years for not investing enough in one of the world's great media brand names and for picking managers who pursued failed strategies.

But Wall Street cheered on Friday when the Bancrofts suddenly said they would consider a $5 billion bid by Rupert Murdoch's News Corp. for the publisher of the Wall Street Journal, after rejecting the proposal last month.


Read more at Reuters Africa